MicroRNA-155 (miR-155) overexpression is often found in malignancies including lung cancer. The objective of this study is to verify the hypothesis, based on the results of bioinformatics analysis, that miR-155 modulates cellular apoptosis and DNA damage through the regulation of Apaf-1 and is thus involved in the development and progression of lung cancer. First, we measured the expression of miR-155 and the Apaf-1 protein in lung cancer tissues. The results showed that expression of miR-155 was significantly higher in lung cancer tissues than in paracancerous and normal tissues; whereas Apaf-1 expression was lower in the lung cancerous tissues. We then established miR-155-silenced and Apaf-1-overexpressed A549 cell lines by transfection with pMAGic2.0-BIC-siRNA and pcDNA3.1-Apaf-1, respectively. These cell lines were then treated with cisplatin, and apoptosis and DNA damage were assessed, with non-transfected A549 cells used as negative controls. The results showed that, relative to controls, the silencing of miR-155 resulted in elevated expression of the Apaf-1 protein, whereas Apaf-1 mRNA levels remained unchanged. Both the silencing of miR-155 and the overexpression Apaf-1 greatly increased the sensitivity of A549 cells to cisplatin treatment, as evidenced by elevated rates of apoptosis and DNA damage. Furthermore, dual-transfection of A549 cells with miR-155 siRNA and Apaf-1 siRNA resulted in the attenuation of apoptosis and DNA damage. In conclusion, the inhibition of miR-155 can enhance the sensitivity of A549 cells to cisplatin treatment by modulation of cellular apoptosis and DNA damage through an Apaf-1-mediated pathway.
INTRODUCTION
MicroRNAs (miRNAs), encoded by miR genes, are a group of short non-coding RNAs prevalent in eukaryotes and play important role in the negative control of gene expression through the cleavage of target mRNAs or the inhibition of translation. [1] [2] [3] [4] [5] To date, more than 700 miRNAs have been identified in mammals and implicated in a variety of cellular processes including proliferation, differentiation, apoptosis, and metabolism. 1, 6 MiR-155 is processed from an exon of a non-coding RNA known as the B-cell Integration Cluster (BIC), which has strong sequence homology among mammals indicating an evolutionarily conserved function. 7 Increasing evidence indicates that miR-155 has distinct expression profiles and plays a role in numerous physiological and pathological processes including haematopoiesis, immunity, inflammation, cancer, and cardiovascular disease. 8 A retrospective analysis showed that miR-155 expression was associated with elevated cancer-specific mortality rates in early-stage, non-small cell lung cancer (NSCLC). 9 Plasma levels of miR-155 were significantly decreased in lung cancer patients who were responsive to chemotherapy. These results indicate that miR-155 has the potential to be a noninvasive biomarker for the early detection and prognosis of lung cancer. 10 In addition, hypoxic conditions induced miR-155 expression in lung cancer cells, and the inhibition of miR-155 by anti-miR-155 molecules enhanced cellular sensitivity to radiation therapy. 11 Therefore, there is evidence that miR-155 functions as an oncogenic microRNA in lung cancers, but information about the molecular mechanisms is still limited.
Cisplatin is a chemotherapeutic agent that is commonly used for the treatment of lung cancers, but resistance to cisplatin and its severe toxic side-effects limit its clinical application. 12 It has been reported that the mechanisms of cisplatin resistance involve increased repair or tolerance of DNA damage and changes, such as failed caspase-9 activation, in apoptotic signaling pathways. 13, 14 Hence, novel strategies to monitor disease progression and to improve responses to cisplatin therapy are required.
The apoptotic protease activating factor 1 (Apaf-1) may be a target for miR-155. In the cytosol, Apaf-1 can bind with cytochrome c released from the mitochondrial inter-membrane, and activate the initiator caspase-9, eventually resulting in cellular apoptosis.
15 BCL2-associated X protein (Bax) is an important factor to destabilize mitochondrial integrity, serving as an essential gateway to mitochondrial dysfunction and activation of the intrinsic apoptotic pathway. We postulated that the deregulation of miR-155 expression could modulate the Apaf-1-related mitochondrial apoptotic pathway and enhance the sensitivity of lung cancer cells to cisplatin treatment.
In this study, we first measured miR-155 and Apaf-1 expression levels in lung cancer tissues. Then, we established A549 cell lines with either silenced miR-155 or overexpression of Apaf-1. Cisplatin-induced DNA damage and apoptosis were then evaluated in the cell lines. A dual-transfection A549 cell line with both miR-155 siRNA and Apaf-1 siRNA was also established to investigate the role of the Apaf-1 apoptotic pathway in cisplatininduced apoptosis and DNA damage. Finally, expression levels of the apoptotic signaling pathway-related proteins caspase-9 and Bax were measured.
MATERIALS AND METHODS

Cells and reagents
The human lung carcinoma cell line A549 was purchased from The American Type Culture Collection (ATCC; Manassas, VA). Cells were cultured in Dulbecco's modified eagle's medium (DMEM) and fetal bovine serum (FBS) (Gibco). Apoptosis detection was performed with the Annexin V-FITC/PI kit (Mbchem, Shanghai, China). RT-PCR was performed with the SYBR Green Real-Time PCR Master Mix Kit (TOYOBO). Transfection related agents Lipofectamine 2000, pcDNA3.1 plasmid, pMAGic2.0/7.0, and T4 DNA ligase were purchased from Invitrogen (Carlsbad, CA). All antibodies were purchased commercially: anti-Apaf-1 (Epitomics), anti-Bax (Santa Cruz Biotechnology), anti-Caspases-9 (Bioworld), anti-GADPH (Multisciences), anti-Rabbit/mouse IgG (H þ L)/HRP (Zhongshan). All other reagents used were analytical grade chemicals. All experiments were replicated at least three times.
Patients and tissue samples
This work was approved by Chinese Ethics Committee of Registering Clinical Trials. A total of eight groups of matched NSCLC cancerous (including 4 adenocarcinomas and 4 squamous carcinomas) and noncancerous tissue samples were surgically obtained from patients in Changzheng Hospital, Shanghai, China. None of the patients had received chemotherapy or radiotherapy before surgery. In each group, the cancerous lung tissue, para-cancerous lung tissue, and normal lung tissue were from different sites of the same patient. Samples were snap-frozen in liquid nitrogen and stored at À 80 1C until RNA and protein extraction. Written informed consent was obtained from all patients before surgery.
Cell culture and treatment
The A549 cells were maintained at 37 1C in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. Cells transfected pMAGic2.0-BIC-siRNA and pcDNA3.1-Apaf-1 were cultured in DMEM supplemented with 25 mg/ml hygromycin and 50 mg/ml genectin, respectively. When the cells grew to 80% confluence, the media were discarded and replaced by fresh medium containing 10 mM of cisplatin, and the cells were cultured for another 24 h. siRNA design, synthesis, and identification BIC-siRNA and Apaf-1-siRNA were designed with online siRNA software from Ambion (http://www.ambion.com/techlib/misc/siRNA_finder.html), and then screened using BLAST software (http://www.ncbi.nlm.nih.gov/ BLAST/) to eliminate potential homological interference. According to sequence of miR-155 host gene (BIC), the 'BIC siRNA' was designed targeting the miR-155 sequence (GCATTTCAAGAACAACCTA). The BICsiRNA and Apaf-1-siRNA sequences were synthesized by the Gima Company (www.genepharma.com) and identified using the Nucleofector technique and RT-PCR.
The BIC siRNA sequence was as follows. . The PCR products were identified by sequence analysis. XbaI and BamHI were added to the synthesized double-stranded cDNA. After being sufficiently digested by the enzymes, Apaf-1 cDNA was purified and recovered with the Promega Wizard SV Gel and PCR Clean-up System. Then the Apaf-1 cDNA was ligated with pcDNA3.1, which had been digested with the same enzymes overnight at 16 1C. The Apaf-1-pcDNA3.1 ligation product was purified with the Plasmid Purification Kit (BIO-RAD) and stored at À 20 1C for transfection.
Cell transfection
For transfections, A549 cells were seeded into 6-well plates at a density of 1 Â 10 5 cells/well. In 2 ml complete medium, they were grown for 2 days until 70-80% confluent. Then, Lipofectamine 2000 (Invitrogen) was used to transfect the BIC-siRNA-pMAGic2.0, Apaf-1-pcDNA3.1, Apaf-1-siRNA-pMAGic2.0, or the control vector according to manufacturer's directions. Transfection complexes were formed at room temperature in serum-free medium, followed by incubation under corresponding antibiotics to select positive stable monoclonal cell lines. Then, the cells were transferred to culture flasks and grown to a high density. For dual transfection, BIC-siRNApMAGic2.0 and Apaf-1-siRNA-pMAGic 7.0 were mixed and incubated with Lipofectamine 2000 in serum-free medium according to manufacturer's directions. The transfection complexes were added to A549 cells and cultured for three days.
Western blot analysis
Cells were lysed in RIPA buffer with proteinase inhibitor cocktail (Roche). Total protein concentration was determined by the BCA Protein Assay Reagent Kit (Pierce). Then it was separated by SDS-PAGE and transfer onto the nitrocellulose membrane for immunoblotting. After incubation with primary and secondary antibodies according to the standard procedure, the chemiluminescence ECL system (Amersham Biosciences) was used to detect protein expression. Quantification of protein band intensities was analyzed by Gel-pre 4 software.
Real-time RT-PCR
Total RNA was extracted from each culture sample using TRIzol. cDNA was synthesized of cDNA was performed using Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (TOYOBO). Then the cDNA (1 mg) was amplified in real time with a 25 ml reaction mixture, which contains SYBR Green PCR Master Mix (TOYOBO), appropriate primer pairs, and water in an ABI Prism 7500 Sequence Detection system (Applied Biosystems). The following RT-PCR primer sets were used: miR-155, 5
0 -CTCTAATGGTGGCA CAAA-3 0 and 5
0 -CCATGGAGAAGGCTGGGG-3 0 and 5 0 -CAAAGTGTCATGGATGACC-3 0 . Specific mRNAs in the samples was quantified relative to the corresponding gene-specific standard curve. RT-PCR reactions were carried out with 5-fold serial dilutions of cDNA as a template. An inverse linear correlation of the Ct value with the template amount ensured a reliable analysis of the mRNA levels. The C t values of each primer set form a standard curve. Its extrapolation reveals the initial quantity of each specific cDNA. All samples were measured in triplicate with the human housekeeping gene b-actin used as a reference to normalize data.
Single cell gel electrophoresis (comet assay) DNA single-strand beaks in treated cells were evaluated by alkaline single cell gel electrophoresis (comet assay). Normal melting agarose (NMA) and low melting agarose (LMA) solutions were prepared in PBS. Sequentially, 100 ml 1% NMA was coated on warm frosted glass microscope slides. Then, after exposure, cells were suspended in 0.7% LMA, and 75 ml of this solution was pipetted onto the first layer of gel. Finally, the third layer (80 ml of 0.5% LMA) was added. After lysis, the slides were subjected to horizontal gel electrophoresis in cooled alkaline buffer at 25 V and 300 mA for 20 min. The slides were soaked twice with neutralization buffer for 8 min and then air-dried. The slides were stained with PI (20 mg/ml) and examied under an Olympus BX-51 fluorescence microscope (Olympus, Japan). Three hundred randomly captured cells from each sample were measured using CASP software (University of Wroclaw, Poland) to quantify the tail lengths and moments.
Analysis of cellular apoptosis
Apoptosis among the A549 cells was assessed using flow cytometry with the Annexin V-FITC/PI detection kit. In brief, cells were plated in 6-well plates at a density of 10 5 cells/well, incubated for 24 h, and then treated with 10 mM cisplatin and incubated for another 24 h. The cells were harvested with 0.25% trypsin and washed twice with cold PBS. Approximately 4 Â 10 5 cells from each sample were suspended in 400 ml binding buffer. Immediately after staining with Annexin V-FITC for 15 min and 10 ml of PI for 5 min, the cells were analyzed by flow cytometry. All of the staining was conducted in the dark. All experiments were repeated at least three times.
Statistical analysis
The results were presented as means ± standard deviation (s.d.) of at least three independent experiments. Statistical differences were analyzed by the SPSS (13.0) software, and a post-hoc Tukey test ascertains the difference between treatment groups and the control. A difference with a two-tailed P-value o0.05 was considered statistically significant.
RESULTS
Expression levels of Apaf-1 and miR-155 in lung cancer, paracancerous, and normal tissues RNA and protein were extracted from eight groups of matched cancerous, paracancerous, and normal tissue samples from patients with NSCLC (including 4 adenocarcinomas and 4 squamous carcinomas). The results showed that Apaf-1 protein level in the cancerous tissues was significantly lower than those in the paracancerous and normal tissues (Figure 1 ). In contrast, the expression of miR-155 levels in the lung cancer tissues was significantly higher than those in the paracancerous and normal tissues (Po0.05, Table 1 ). Moreover, the miR-155 levels in the paracancerous was higher than those in normal tissues, but lower than those in cancer tissues. The Apaf-1 protein expression levels were also between the levels of cancer tissues and normal tissues, indicating the expression of Apaf-1 and miR-155 might involve the progression of lung cancer.
Expression levels of miR-155 and Apaf-1 in A549 cells transfected with BIC-siRNA-pMAGic2.0 or Apaf-1-pcDNA3.1 Quantitative RT-PCR was performed to detect the transcriptional expression levels of miR-155 and Apaf-1 in A549 cells, which have been transfected with control DNA, BIC-siRNA-pMAGic2.0, or Apaf-1-pcDNA3.1, respectively. As shown on Table 2 , compared to the control group, transfection with Apaf-1-pcDNA3.1 significantly increased the exogenous expression of Apaf-1, whereas transfection with BIC-siRNA-pMAGic2.0 markedly decreased expression of miR-155 (Po0.05). The Apaf-1 mRNA levels in the group transfected with BIC-siRNA-pMAGic2.0 and the miR-155 levels in the group transfected with Apaf-1-pcDNA3.1 showed no significant changes (P40.05 for both comparisons). Western blot results showed, however, that levels of the Apaf-1 protein were clearly elevated in both the Apaf-1-pcDNA3.1-transfected group and the BIC-siRNA-pMAGic2.0-transfected group (Figure 2 ).
The effects of transfection with BIC-siRNA-pMAGic2.0 or Apaf-1-pcDNA3.1 on DNA damage and apoptosis induced by cisplatin treatment Single-cell gel electrophoresis assays were conducted to measure DNA damage induced by cisplatin treatment. As shown in Figures  3a and b , transfection with the plasmids pcDNA3.1 or pMAGic2.0 Figure 1 . Expression levels of Apaf-1 in the lung cancer, paracancerous, and normal tissues. Western blotting was conducted to measure the Apaf-1 protein levels in lung cancer (C), paracancerous (P), and normal (N) tissues, using GAPDH as an internal reference. Each experiment was repeated three times and the figure was from the result of a typical experiment. AC represents adenocarcinomas and SC represents squamous carcinomas through histologic diagnosis. Figures 3c and d , transfection with the plasmids pcDNA3.1 or pMAGic2.0 alone did not induce significant levels of apoptosis (P40.05). Transfection with BIC-siRNA-pMAGic2.0 or Apaf-1-pcDNA3.1, however, caused slightly increased levels of apoptosis in A549 cells (Po0.05). Combination treatment of cisplatin and BIC-siRNA-pMAGic2.0 or Apaf-1-pcDNA3.1 transfection resulted in significantly elevated levels of apoptosis (Po0.01), which were also markedly higher than those caused by the vectors alone or plus empty vector (Po0.05).
The effects of dual-transfection with BIC-siRNA-pMAGic2.0 and Apaf-1-siRNA-pMAGic7.0 on DNA damage and apoptosis To evaluate the influence of Apaf-1 expression on the DNA damage and cellular apoptosis, A549 cells were dual-transfected with BIC-siRNA-pMAGic2.0 and Apaf-1-siRNA-pMAGic7.0. As shown in Figure 4 , transfection with BIC-siRNA-pMAGic2.0 caused markedly elevated levels of DNA damage and cellular apoptosis compared with the control group or the pMAGic2.0 group (Po0.05). Levels of DNA damage and cellular apoptosis in the dual-transfection group, however, were significantly lower (Po0.05).
The effect of miR-155 down-regulation on the expression of related proteins in the Apaf-1 apoptotic pathway MiR-155 in A549 cells was down-regulated by siRNA, and expression levels of the Apaf-1 apoptotic pathway proteins caspase-9 and Bax were measured by Western blot assays. As shown in Figure 5 , treatment with BIC-siRNA-pMAGic2.0 þ cisplatin resulted in significant elevation of caspase-9 and Bax, which is higher than that caused by pMAGic2.0 þ cisplatin or BICsiRNA-pMAGic2.0.
DISCUSSION
It is well known that miRNAs are involved in many aspects of physical and biological processes, such as differentiation, the survival and function of immune cells, and intracellular signaling pathways. 16 MiR-155 functions as an oncogene and plays a role in the development and progression of lung cancer, with a significant impact on diagnosis and prognosis. 7, [17] [18] [19] Furthermore, some reports have indicated, however, that miR-155 could also exert a possible tumor-suppression function by suppressing the c-myc pathway. 20 Qin et al. found that miR-155 significantly inhibits the growth of human lung cancer 95D cells in vitro through the induction of G0/G1 phase arrest. 21 The exact role of miR-155 in the pathogenesis and development of lung cancer remains to be elucidated.
We evaluated the expression levels of miR-155 and Apaf-1 in matched lung cancer and noncancerous tissue samples. The results showed that the expression of the Apaf-1 protein (4) BIC-siRNA-pMAGic2.0, and then Western blots were performed to measure Apaf-1 expression levels, using GAPDH as an internal reference. Each experiment was repeated three times and the result was from a typical experiment. was significantly reduced in the cancerous tissues, both adenocarcinomas and squamous carcinomas, compared with paracancerous and normal tissues. In contrast, the expression of miR-155 was significantly elevated in the cancerous tissues, indicating that miR-155 might be involved in the development and progression of carcinogenesis.
To further clarify the roles of miR-155 and Apaf-1 in the progression of lung cancer, we established a model system via BIC-siRNA or Apaf-1 cDNA transfection in lung adenocarcinoma A549 cells. We found that down-regulation of miR-155 by siRNA in A549 cells was correlated to elevated levels of the Apaf-1 protein without obvious changes in its transcriptional expression. This indicates that the Apaf-1 protein might be modulated by miR-155 at the translational level. A bioinformatical analysis of the Human and Drosophila miRNA targets (http://www.microrna.org) and Targetscan-Mammalian miRNA targets (http://genes.mit.edu/targetscan) also showed that the 3 0 UTR of Apaf-1 has nucleotide sequences complementary to miR-155.
Apaf-1 is a core molecule in the mitochondrial apoptotic pathway, relaying the death signal to the heptameric apoptosome complex to ignite the downstream cascade of caspases. 22 The multimeric Apaf-1/cytochrome c apoptosome recruits procaspase-9 molecules, and the bound caspase-9 is then able to efficiently cleave and activate downstream executioner caspases such as caspase-3. 23, 24 Cells depleted of Apaf-1 are resistant to apoptosis induced by the DNA-damaging anticancer drug etoposide. 25, 26 Therefore, the elevation of Apaf-1 caused by the down-regulation of miR-155 may affect cellular DNA damage and apoptosis. Our results showed that transfection with BIC-siRNA-pMAGic2.0 or Apaf-1-pcDNA3.1 caused increased DNA damage in A549 cells. Combining treatment of cisplatin and transfection with BIC-siRNApMAGic2.0 or Apaf-1-pcDNA3.1 resulted in significantly elevated DNA damage and apoptosis. It is reported that miR-155 inhibition is involved in sensitizing breast cancer cells to DNA damaging chemotherapeutics by targeting FOXO3a. 27 Additionally, the role of miR-155 in sensitizing cells to cisplatin treatment has already been shown in macrophages in a TLR-and type IV secretion system-dependent way. 28 Furthermore, dual-transfection with BICsiRNA-pMAGic2.0 and Apaf-1-siRNA-pMAGic7.0 significantly alleviated the DNA damage and apoptosis induced by the down-regulation of miR-155. These results indicate that the down-regulation of miR-155 could enhance the sensitivity of A549 cells to cisplatin treatment via restoration of the Apaf-1 pathway.
Our results showed that down-regulation of miR-155 caused elevated expression levels of the Apaf-1 apoptotic pathway proteins caspase-9 and Bax. The A549 cells transfected with BICsiRNA-pMAGic2.0 showed even higher levels of caspase-9 and Bax after treatment with cisplatin, suggesting that the cisplatininduced DNA damage and cellular apoptosis might be regulated by the Apaf-1-associated mitochondrial pathway. As most chemotherapy agents function via induction of DNA damage and cellular apoptosis, the sensitivity of cancer cells to these agents can be affected by deregulation of cellular apoptotic pathways. Crawford et al. found that selection for platinum resistance was associated with a block of mitochondrial death signaling upstream of BAX/BAK activation. 29 The novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2, and Bax in osteosarcoma cells. 30 Thus the alteration of cisplatin sensitivity induced by miR-155 down-regulation in A549 cells might also be related to the Apaf-1 apoptotic pathway.
In summary, Apaf-1 is a target of miR-155 and down regulation of miR-155 can enhance the sensitivity of A549 human lung carcinoma cells to cisplatin treatment through the induction of DNA damage and apoptosis via the restoration of the mitochondrial apoptotic pathway. Molecules targeting miR-155 and Apaf-1 may have clinical applications in the development of novel strategies for lung cancer treatment.
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